Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment
Non-small cell lung cancer is still diagnosed at a late disease stage and systematic therapy is necessary. Currently we have three main treatment modalities; chemotherapy, targeted with tyrosine kinase inhibitors and immune check point inhibitors. In the recent years and based on new studies we can...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294223000795 |
| _version_ | 1797387815844052992 |
|---|---|
| author | Paul Zarogoulidis Dimitris Matthaios Panagoula Oikonomou Christina Nikolaou Charalampos Charalampidis Chrysanthi Sardeli |
| author_facet | Paul Zarogoulidis Dimitris Matthaios Panagoula Oikonomou Christina Nikolaou Charalampos Charalampidis Chrysanthi Sardeli |
| author_sort | Paul Zarogoulidis |
| collection | DOAJ |
| description | Non-small cell lung cancer is still diagnosed at a late disease stage and systematic therapy is necessary. Currently we have three main treatment modalities; chemotherapy, targeted with tyrosine kinase inhibitors and immune check point inhibitors. In the recent years and based on new studies we can administer combination of chemotherapy and immunotherapy, or radiotherapy and immunotherapy. Every treatment approach is based on the specific gene expression of the tumor. Tyrosine kinase inhibitors have been used for more than a decade for epidermal growth factor positive tumors, the same for anaplastic lymphoma kinase and proto-oncogene 1. Programmed death-ligand 1 expression has been found to be associated with the efficiency of immune checkpoint inhibitors. However; there are still several subpopulations in non-small cell lung cancer patients. We will comment on the group with KRAS G12C mutation and the targeted therapy with sotorasib for its efficiency and toxicity based on new studies. |
| first_indexed | 2024-03-08T22:31:35Z |
| format | Article |
| id | doaj.art-a826e5ef7af34f75aef1fc84b1c70839 |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-03-08T22:31:35Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-a826e5ef7af34f75aef1fc84b1c708392023-12-18T04:24:41ZengElsevierCancer Treatment and Research Communications2468-29422023-01-0137100757Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatmentPaul Zarogoulidis0Dimitris Matthaios1Panagoula Oikonomou2Christina Nikolaou3Charalampos Charalampidis4Chrysanthi Sardeli5Pulmonary Department, General Clinic Euromedica, Thessaloniki, Greece; 3rd University Surgery Department, ``AHEPA`` University Hospital, Thessaloniki, Greece; Corresponding author at: Pulmonary Department, General Clinic Euromedica, Thessaloniki, Greece.Oncology Department, General Hospital of Rhodes, GreeceSurgery Department, Democritus University of Thrace, Alexandroupolis, GreeceSurgery Department, Democritus University of Thrace, Alexandroupolis, GreeceDepartment of Pathology, University of Cyprus, CyprusDepartment of Pharmacology & Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceNon-small cell lung cancer is still diagnosed at a late disease stage and systematic therapy is necessary. Currently we have three main treatment modalities; chemotherapy, targeted with tyrosine kinase inhibitors and immune check point inhibitors. In the recent years and based on new studies we can administer combination of chemotherapy and immunotherapy, or radiotherapy and immunotherapy. Every treatment approach is based on the specific gene expression of the tumor. Tyrosine kinase inhibitors have been used for more than a decade for epidermal growth factor positive tumors, the same for anaplastic lymphoma kinase and proto-oncogene 1. Programmed death-ligand 1 expression has been found to be associated with the efficiency of immune checkpoint inhibitors. However; there are still several subpopulations in non-small cell lung cancer patients. We will comment on the group with KRAS G12C mutation and the targeted therapy with sotorasib for its efficiency and toxicity based on new studies.http://www.sciencedirect.com/science/article/pii/S2468294223000795Non-small cell lung cancerEbusRadial ebusCell blockChemotherapyImmunotherapy |
| spellingShingle | Paul Zarogoulidis Dimitris Matthaios Panagoula Oikonomou Christina Nikolaou Charalampos Charalampidis Chrysanthi Sardeli Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment Cancer Treatment and Research Communications Non-small cell lung cancer Ebus Radial ebus Cell block Chemotherapy Immunotherapy |
| title | Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment |
| title_full | Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment |
| title_fullStr | Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment |
| title_full_unstemmed | Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment |
| title_short | Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment |
| title_sort | sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity true false or just another adverse effect of nsclc treatment |
| topic | Non-small cell lung cancer Ebus Radial ebus Cell block Chemotherapy Immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2468294223000795 |
| work_keys_str_mv | AT paulzarogoulidis sotorasibafterimmunecheckpointinhibitoradministrationinduceshepatotoxicitytruefalseorjustanotheradverseeffectofnsclctreatment AT dimitrismatthaios sotorasibafterimmunecheckpointinhibitoradministrationinduceshepatotoxicitytruefalseorjustanotheradverseeffectofnsclctreatment AT panagoulaoikonomou sotorasibafterimmunecheckpointinhibitoradministrationinduceshepatotoxicitytruefalseorjustanotheradverseeffectofnsclctreatment AT christinanikolaou sotorasibafterimmunecheckpointinhibitoradministrationinduceshepatotoxicitytruefalseorjustanotheradverseeffectofnsclctreatment AT charalamposcharalampidis sotorasibafterimmunecheckpointinhibitoradministrationinduceshepatotoxicitytruefalseorjustanotheradverseeffectofnsclctreatment AT chrysanthisardeli sotorasibafterimmunecheckpointinhibitoradministrationinduceshepatotoxicitytruefalseorjustanotheradverseeffectofnsclctreatment |